Navigation Links
Clinical studies in the pipeline: the therapies of tomorrow in trials today
Date:10/23/2007

SAN FRANCISCO Studies presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrate the flexibility of targeted therapy techniques, where new drugs can be developed and tested in human trials more quickly and safely than ever before.

Among the studies presented include a pair of reports on two separate novel insulin-like growth factor receptor enzyme inhibitors, both currently involved in solid tumor clinical trials. In addition, researchers will be offering details on two Phase II trials involving already-approved drugs in new applications: sunitinib in a form of liver cancer and sorafenib, combined with the cell-signaling molecule IL-21, in metastatic renal cancer.

Efficacy, safety, and changes in angiogenic markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a phase II study: Abstract PR 7.

Use of sunitinib, designed to reduce tumor angiogenesis, appears to offer early evidence of antitumor activity for patients with a difficult to treat liver cancer known as advanced hepatocellular carcinoma (HCC), say researchers at Dana Farber Harvard Cancer Center.

Results from a 30-patient Phase II study in HCC of the agent, which is approved for use in kidney and rare stomach cancers, show that cancer stabilized in 10 patients for at least three months while one patient had a partial response. Overall, the agent offered a progression-free survival of four months, says the studys lead investigator, Andrew X. Zhu, M.D., Ph.D., an attending oncologist at Massachusetts General Hospital Cancer Center and an assistant professor of medicine at Harvard Medical School.

We have seen preliminary evidence of anti-tumor activity, and although it is modest, it is also encouraging because all of these patients have cancer that cannot be removed by surgery or which has metastasized, Dr. Zhu said. This is a small, single a
'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... NJ. April 10, 2014. John DeLuca, PhD, and Yael ... Idec to study how persons with multiple sclerosis (MS) ... of Actual Reality to Measure Everyday Life Functional Activity ... research. Dr. DeLuca is senior VP of Research & ... at New York University, is a visiting scientist at ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... COLUMBUS, Ohio A new study identifies a molecule ... and suggests that the molecule could be an important ... of tumor progression. , The study of microRNA-135b (miR-135b) ... in the journal Cancer Cell and was ... Cancer Center Arthur G. James Cancer Hospital and ...
(Date:4/14/2014)... --- Depression can hit young fathers hard -- with symptoms ... their children,s lives, a new Northwestern Medicine study has found. ... the first five years of fatherhood for these young men, ... and whom lived in the same home as their children. ... the journal Pediatrics . , This study is the ...
(Date:4/14/2014)... world, many people live and work in dim and ... And as the global population continues to rise and ... spread. , To alleviate the problem, Egyptian researchers ... onto narrow streets and alleyways. The panel is mounted ... angle, where it spreads sunlight onto the street below. ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... Feb. 25 Omnicell, Inc.,(Nasdaq: OMCL ), a ... today that its Board of Directors has approved the,repurchase ... its Common Stock over,the next 12 months. The Company,s ... after a review of the Company,s financial position and,investment ...
... -- Up to 20 percent of patients taking aspirin ... event do not have an antiplatelet response from aspirin, ... at the University at Buffalo have shown. , ... of a second stroke, second heart attack or second ...
... HILL Bacteria mutate for a living, evading antibiotic drugs ... States each year. But as concern about drug-resistant bacteria grows, ... Carolina at Chapel Hill seeks to thwart the bug without ... Mark Schoenfisch and his lab of analytical chemists at UNC ...
... GmbH, a Systems Biology company focussed on high quality ... showcasing its abilities in the analysis of data generated ... Boyle et al published in the January 2008 issue ... of Open Chromatin across the Genome where they identified ...
... 25 Danaher Corporation,(NYSE: DHR ) announced ... Jr. will be presenting at the Citigroup Global ... March 5 at 8:00,a.m. EST. The audio will ... will be archived on, http://www.danaher.com for one ...
... new blockages within 3 years, study finds , , ... a blood clot in their legs (deep vein thrombosis) ... of developing another blood clot within three years, a ... embolism are known collectively as venous thromboembolism. , Researchers ...
Cached Medicine News:Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3Health News:Many stroke, heart attack patients may not benefit from aspirin 2Health News:Many stroke, heart attack patients may not benefit from aspirin 3Health News:Silica smart bombs deliver knock-out to bacteria 2Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2Health News:Blood Clots in Legs, Lungs Predispose Patients to Repeat Episodes 2
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an ... for patients to self-inject prescription drugs in the large ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... expected to grow to $220B by 2018, according to ... type of injector that does not exist today for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Vista Partners announced today that it has ... "Company") and raised its twelve month target price to AUD ... is on track to enter clinical trials for its AMI ... The Company recently completed humanisation of its "first in class" ...
... of brand drug "copay coupon" promotions, which lure insured ... costs by $681 million in Missouri over the next ... to new research from Visante and released by the ... of these promotions by state and local government workers ...
Cached Medicine Technology:Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $681 Million in Missouri 2
... Technology, multi-frequency, linear micro-surgery transducer. ... very helpful in tight situations. ... a choice transducer for pediatric ... high frequency upper end makes ...
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n...
Medicine Products: